Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 3 institutions in 1 country.
Thurston Herricks *Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, United States.ORCID 0000-0002-0247-7967
Magdalena Donczew *Department of Microbiology, University of Washington, Seattle, United States.
Fred D MastCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, United States.ORCID 0000-0002-2177-6647
Tige RustadCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, United States.
Robert MorrisonCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, United States.
Timothy R SterlingDivision of Infectious Disease, Department of Medicine, Vanderbilt University Medical Center, Nashville, United States.
David R ShermanDepartment of Microbiology, University of Washington, Seattle, United States.
John D AitchisonCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, United States.ORCID 0000-0002-9153-6497
Infectious Disease Research Institute · USUniversity of Washington · USVanderbilt University Medical Center · US
Funding
Validation and Application of a Model for Human-like TB Latency in RabbitsU19AI111276 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI ALLAND, DAVID, ALLAND, DAVID · 2014 to 2020
$23.3M
TR&D Project 4. The Imaging Stage: Multiscale Spatiotemporal Modeling of Macromolecular Systems in Cellular NeighborhoodsP41GM109824 · NIGMS · ROCKEFELLER UNIVERSITY · PI ROUT, MICHAEL P · 2014 to 2023
$18.8M
Technology CoreU19AI135976 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI ADEREM, ALAN A · 2018 to 2022
$17.0M
Systems Biology CoreU19AI162598 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI SHERMAN, DAVID R · 2021 to 2025
$13.9M
Site Specific Immunophenotyping Assays of COVID19 Patients to Align with NIAID National StudyR01AI141953 · NIAID · INSTITUTE FOR SYSTEMS BIOLOGY · PI BALIGA, NITIN S · 2019 to 2023
$5.7M
Fluoroquinolone Resistance in M. TuberculosisR01AI063200 · NIAID · VANDERBILT UNIVERSITY · PI STERLING, TIMOTHY R · 2006 to 2010
$1.8M
Fluoroquinolones and Efflux-Mediated Cross Resistance in HIV-related TBR56AI118361 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SHERMAN, DAVID R, STERLING, TIMOTHY R · 2016 to 2016
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
ODELAM, rapid sequence-independent detection of drug resistance in isolates of · full record | OpenQuestion